Xarelto And Pradaxa Stumble At High U.K. Reimbursement Hurdles
This article was originally published in The Pink Sheet Daily
Executive Summary
NICE issues draft rejection of Bayer's blood thinner Xarelto for use in preventing stroke associated with atrial fibrillation, while a U.K. payer fights a positive recommendation for Boehringer Ingelheim's Pradaxa in the same indication.